You are here

Article Text

Article menu
Download PDFPDF
Case Reports: Rare disease
Membranous nephropathy after a recent SARS-CoV-2 infection
  1. Catarina Mateus1,
  2. Rita Theias Manso2,
  3. Ana Rita Martins1 and
  4. Patrícia Quadros Branco1
  1. 1Nephrology Department, Centro Hospitalar de Lisboa Ocidental EPE Hospital de Santa Cruz, Carnaxide, Lisboa, Portugal
  2. 2Pathology Department, Centro Hospitalar de Lisboa Ocidental EPE Hospital de Egas Moniz, Lisboa, Portugal
  1. Correspondence to Dr Catarina Mateus; ana.catarina.mateus{at}gmail.com

Abstract

SARS-CoV-2 infections can induce kidney injury and glomerulopathy, with the most common pathology findings being acute tubular injury and collapsing glomerulopathy.

Here we describe a rare case of membranous nephropathy in a man in his late 70s presented with nephrotic syndrome and rapidly progressive kidney dysfunction 1 month after SARS-CoV-2 infection. Phospholipase A2 receptor antibodies were positive. He was treated with rituximab, with proteinuria control. We review the cases reported in the literature.

  • COVID-19
  • Renal system
  • Nephrotic syndrome

http://dx.doi.org/10.1136/bcr-2022-252468

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors CM wrote the original draft. RTM recorded biopsy images, reviewed and edited the manuscript. ARM and PQB reviewed and edited the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.